These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 20932759)

  • 1. 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors.
    Beria I; Valsasina B; Brasca MG; Ceccarelli W; Colombo M; Cribioli S; Fachin G; Ferguson RD; Fiorentini F; Gianellini LM; Giorgini ML; Moll JK; Posteri H; Pezzetta D; Roletto F; Sola F; Tesei D; Caruso M
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6489-94. PubMed ID: 20932759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.
    Beria I; Ballinari D; Bertrand JA; Borghi D; Bossi RT; Brasca MG; Cappella P; Caruso M; Ceccarelli W; Ciavolella A; Cristiani C; Croci V; De Ponti A; Fachin G; Ferguson RD; Lansen J; Moll JK; Pesenti E; Posteri H; Perego R; Rocchetti M; Storici P; Volpi D; Valsasina B
    J Med Chem; 2010 May; 53(9):3532-51. PubMed ID: 20397705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
    Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B
    Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors.
    Caldarelli M; Angiolini M; Disingrini T; Donati D; Guanci M; Nuvoloni S; Posteri H; Quartieri F; Silvagni M; Colombo R
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4507-11. PubMed ID: 21723120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.
    Rheault TR; Donaldson KH; Badiang-Alberti JG; Davis-Ward RG; Andrews CW; Bambal R; Jackson JR; Cheung M
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4587-92. PubMed ID: 20594842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
    Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
    Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
    Chembiochem; 2009 May; 10(7):1145-8. PubMed ID: 19350612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.
    Emmitte KA; Adjabeng GM; Andrews CW; Alberti JG; Bambal R; Chamberlain SD; Davis-Ward RG; Dickson HD; Hassler DF; Hornberger KR; Jackson JR; Kuntz KW; Lansing TJ; Mook RA; Nailor KE; Pobanz MA; Smith SC; Sung CM; Cheung M
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1694-7. PubMed ID: 19237286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
    Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
    Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selectivity-determining residues in Plk1.
    Kothe M; Kohls D; Low S; Coli R; Rennie GR; Feru F; Kuhn C; Ding YH
    Chem Biol Drug Des; 2007 Dec; 70(6):540-6. PubMed ID: 18005335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1.
    Richter S; Neundorf I; Loebner K; Gräber M; Berg T; Bergmann R; Steinbach J; Pietzsch J; Wuest F
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4686-9. PubMed ID: 21778054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.
    Zhang Q; Xia Z; Mitten MJ; Lasko LM; Klinghofer V; Bouska J; Johnson EF; Penning TD; Luo Y; Giranda VL; Shoemaker AR; Stewart KD; Djuric SW; Vasudevan A
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7615-22. PubMed ID: 23103095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
    Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
    Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
    Lu S; Sun SL; Liu HC; Chen YD; Yuan HL; Gao YP; Yang P; Lu T
    Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation.
    Egert-Schmidt AM; Dreher J; Dunkel U; Kohfeld S; Preu L; Weber H; Ehlert JE; Mutschler B; Totzke F; Schächtele C; Kubbutat MH; Baumann K; Kunick C
    J Med Chem; 2010 Mar; 53(6):2433-42. PubMed ID: 20170163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance.
    McInnes C; Mazumdar A; Mezna M; Meades C; Midgley C; Scaerou F; Carpenter L; Mackenzie M; Taylor P; Walkinshaw M; Fischer PM; Glover D
    Nat Chem Biol; 2006 Nov; 2(11):608-17. PubMed ID: 17028581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).
    Duffey MO; Vos TJ; Adams R; Alley J; Anthony J; Barrett C; Bharathan I; Bowman D; Bump NJ; Chau R; Cullis C; Driscoll DL; Elder A; Forsyth N; Frazer J; Guo J; Guo L; Hyer ML; Janowick D; Kulkarni B; Lai SJ; Lasky K; Li G; Li J; Liao D; Little J; Peng B; Qian MG; Reynolds DJ; Rezaei M; Scott MP; Sells TB; Shinde V; Shi QJ; Sintchak MD; Soucy F; Sprott KT; Stroud SG; Nestor M; Visiers I; Weatherhead G; Ye Y; D'Amore N
    J Med Chem; 2012 Jan; 55(1):197-208. PubMed ID: 22070629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1).
    Nie Z; Feher V; Natala S; McBride C; Kiryanov A; Jones B; Lam B; Liu Y; Kaldor S; Stafford J; Hikami K; Uchiyama N; Kawamoto T; Hikichi Y; Matsumoto S; Amano N; Zhang L; Hosfield D; Skene R; Zou H; Cao X; Ichikawa T
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3662-6. PubMed ID: 23664874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
    Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
    Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.